IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v558y2018i7710d10.1038_s41586-018-0111-5.html
   My bibliography  Save this article

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Author

Listed:
  • Loren M. Lasko

    (Discovery, Global Pharmaceutical Research and Development)

  • Clarissa G. Jakob

    (Discovery, Global Pharmaceutical Research and Development)

  • Rohinton P. Edalji

    (Discovery, Global Pharmaceutical Research and Development)

  • Wei Qiu

    (Discovery, Global Pharmaceutical Research and Development)

  • Debra Montgomery

    (Discovery, Global Pharmaceutical Research and Development)

  • Enrico L. Digiammarino

    (Discovery, Global Pharmaceutical Research and Development)

  • T. Matt Hansen

    (Discovery, Global Pharmaceutical Research and Development)

  • Roberto M. Risi

    (Discovery, Global Pharmaceutical Research and Development)

  • Robin Frey

    (Discovery, Global Pharmaceutical Research and Development)

  • Vlasios Manaves

    (Discovery, Global Pharmaceutical Research and Development)

  • Bailin Shaw

    (Discovery, Global Pharmaceutical Research and Development)

  • Mikkel Algire

    (Discovery, Global Pharmaceutical Research and Development)

  • Paul Hessler

    (Discovery, Global Pharmaceutical Research and Development)

  • Lloyd T. Lam

    (Discovery, Global Pharmaceutical Research and Development)

  • Tamar Uziel

    (Discovery, Global Pharmaceutical Research and Development)

  • Emily Faivre

    (Discovery, Global Pharmaceutical Research and Development)

  • Debra Ferguson

    (Discovery, Global Pharmaceutical Research and Development)

  • Fritz G. Buchanan

    (Discovery, Global Pharmaceutical Research and Development)

  • Ruth L. Martin

    (Discovery, Global Pharmaceutical Research and Development)

  • Maricel Torrent

    (Discovery, Global Pharmaceutical Research and Development)

  • Gary G. Chiang

    (Discovery, Global Pharmaceutical Research and Development
    eFFECTOR Therapeutics)

  • Kannan Karukurichi

    (Petra Pharma Corporation)

  • J. William Langston

    (Faraday Pharmaceuticals)

  • Brian T. Weinert

    (University of Copenhagen)

  • Chunaram Choudhary

    (University of Copenhagen)

  • Peter Vries

    (Cascadian Therapeutics, Inc.)

  • Arthur F. Kluge

    (I-to-D, Inc.)

  • Michael A. Patane

    (Mitobridge, Inc.)

  • John H. Drie

    (Van Drie Research)

  • Ce Wang

    (China Novartis Institutes for BioMedical Research)

  • David McElligott

    (Accelerator Corporation)

  • Edward A. Kesicki

    (Petra Pharma Corporation)

  • Ronen Marmorstein

    (University of Pennsylvania)

  • Chaohong Sun

    (Discovery, Global Pharmaceutical Research and Development)

  • Philip A. Cole

    (Johns Hopkins University)

  • Saul H. Rosenberg

    (Discovery, Global Pharmaceutical Research and Development)

  • Michael R. Michaelides

    (Discovery, Global Pharmaceutical Research and Development)

  • Albert Lai

    (Discovery, Global Pharmaceutical Research and Development)

  • Kenneth D. Bromberg

    (Discovery, Global Pharmaceutical Research and Development)

Abstract

In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author ‘Edward A. Kesicki’ was misspelled as ‘Ed Kesicki’. These errors have been corrected online.

Suggested Citation

  • Loren M. Lasko & Clarissa G. Jakob & Rohinton P. Edalji & Wei Qiu & Debra Montgomery & Enrico L. Digiammarino & T. Matt Hansen & Roberto M. Risi & Robin Frey & Vlasios Manaves & Bailin Shaw & Mikkel A, 2018. "Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours," Nature, Nature, vol. 558(7710), pages 1-1, June.
    • Handle: RePEc:nat:nature:v:558:y:2018:i:7710:d:10.1038_s41586-018-0111-5
    DOI: 10.1038/s41586-018-0111-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-018-0111-5
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-018-0111-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:558:y:2018:i:7710:d:10.1038_s41586-018-0111-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.